Novo’s Wegovy beats Lilly’s Zepbound in real-world study for heart diseases Seeking Alpha Weight loss drugs can halve heart patients’ risk of early death, study finds The Guardian Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease PR Newswire Weight loss jabs could keep heart failure …
Read More »